27 USD
-0.88 (-3.16%)
Taking everything into account, VTVT scores 3 out of 10 in our fundamental rating. VTVT was compared to 533 industry peers in the Biotechnology industry. While VTVT has a great health rating, there are worries on its profitability. While showing a medium growth rate, VTVT is valued expensive at the moment.
1. Profitability
1.1 Basic Checks
VTVT had negative earnings in the past year.
VTVT had a negative operating cash flow in the past year.
In the past 5 years VTVT always reported negative net income.
VTVT had a negative operating cash flow in each of the past 5 years.
1.2 Ratios
VTVT has a better Return On Assets (-23.59%) than 73.36% of its industry peers.
The Return On Equity of VTVT (-33.27%) is better than 75.23% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.59% | ||
| ROE | -33.27% | ||
| ROIC | N/A |
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
The Profit Margin and Operating Margin and Gross Margin are not available for VTVT so they could not be analyzed.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
2. Health
2.1 Basic Checks
VTVT does not have a ROIC to compare to the WACC, probably because it is not profitable.
The number of shares outstanding for VTVT has been increased compared to 1 year ago.
VTVT has less shares outstanding than it did 5 years ago.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
Based on the Altman-Z score of -2.62, we must say that VTVT is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of VTVT (-2.62) is comparable to the rest of the industry.
There is no outstanding debt for VTVT. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Altman-Z | -2.62 |
ROIC/WACCN/A
WACC8.63%
2.3 Liquidity
VTVT has a Current Ratio of 9.79. This indicates that VTVT is financially healthy and has no problem in meeting its short term obligations.
VTVT has a better Current ratio (9.79) than 80.68% of its industry peers.
VTVT has a Quick Ratio of 9.79. This indicates that VTVT is financially healthy and has no problem in meeting its short term obligations.
Looking at the Quick ratio, with a value of 9.79, VTVT belongs to the top of the industry, outperforming 81.05% of the companies in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 9.79 | ||
| Quick Ratio | 9.79 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 24.84% over the past year.
VTVT shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.30%.
VTVT shows a very negative growth in Revenue. Measured over the last years, the Revenue has been decreasing by -18.10% yearly.
EPS 1Y (TTM)24.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.17%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%N/A
3.2 Future
VTVT is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 4.92% yearly.
The Revenue is expected to grow by 112.47% on average over the next years. This is a very strong growth
EPS Next Y0.14%
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
EPS Next 5Y4.92%
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%
3.3 Evolution
The Revenue growth rate is accelerating: in the next years the growth will be better than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
VTVT reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for VTVT. No positive earnings are expected for the next year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
VTVT's earnings are expected to decrease with -4.37% in the coming years. This may justify a cheaper valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
5. Dividend
5.1 Amount
VTVT does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
NASDAQ:VTVT (11/26/2025, 8:08:27 PM)
27
-0.88 (-3.16%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)
Earnings (Next)
Inst Owners39.63%
Inst Owner Change68.15%
Ins Owners0.63%
Ins Owner Change0%
Market Cap86.13M
Revenue(TTM)17.00K
Net Income(TTM)-23.47M
Analysts82.5
Price Target36.21 (34.11%)
Short Float %1.15%
Short Ratio2.98
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)0
Avg EPS beat(2)-8.69%
Min EPS beat(2)-9.33%
Max EPS beat(2)-8.04%
EPS beat(4)2
Avg EPS beat(4)7.01%
Min EPS beat(4)-9.33%
Max EPS beat(4)38.02%
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)12.75%
EPS NQ rev (3m)12.75%
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | 5066.47 | ||
| P/FCF | N/A | ||
| P/OCF | N/A | ||
| P/B | 1.22 | ||
| P/tB | 1.22 | ||
| EV/EBITDA | N/A |
EPS(TTM)-3.32
EYN/A
EPS(NY)-3.82
Fwd EYN/A
FCF(TTM)-6.53
FCFYN/A
OCF(TTM)-6.53
OCFYN/A
SpS0.01
BVpS22.11
TBVpS22.11
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | -23.59% | ||
| ROE | -33.27% | ||
| ROCE | N/A | ||
| ROIC | N/A | ||
| ROICexc | N/A | ||
| ROICexgc | N/A | ||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | N/A | ||
| FCFM | N/A |
ROA(3y)-96.56%
ROA(5y)-79.63%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | N/A | ||
| Debt/EBITDA | N/A | ||
| Cap/Depr | N/A | ||
| Cap/Sales | N/A | ||
| Interest Coverage | N/A | ||
| Cash Conversion | N/A | ||
| Profit Quality | N/A | ||
| Current Ratio | 9.79 | ||
| Quick Ratio | 9.79 | ||
| Altman-Z | -2.62 |
F-Score4
WACC8.63%
ROIC/WACCN/A
Cap/Depr(3y)7.41%
Cap/Depr(5y)4.44%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)24.84%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-23.17%
EPS Next Y0.14%
EPS Next 2Y-1.29%
EPS Next 3Y-4.37%
EPS Next 5Y4.92%
Revenue 1Y (TTM)-98.3%
Revenue growth 3Y-36.7%
Revenue growth 5Y-18.1%
Sales Q2Q%N/A
Revenue Next Year-100%
Revenue Next 2Y-41.42%
Revenue Next 3Y-25.99%
Revenue Next 5Y112.47%
EBIT growth 1Y-24.26%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y9.64%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y9.64%
OCF growth 3YN/A
OCF growth 5YN/A
VTV THERAPEUTICS INC- CL A / VTVT FAQ
What is the fundamental rating for VTVT stock?
ChartMill assigns a fundamental rating of 3 / 10 to VTVT.
What is the valuation status of VTV THERAPEUTICS INC- CL A (VTVT) stock?
ChartMill assigns a valuation rating of 0 / 10 to VTV THERAPEUTICS INC- CL A (VTVT). This can be considered as Overvalued.
Can you provide the profitability details for VTV THERAPEUTICS INC- CL A?
VTV THERAPEUTICS INC- CL A (VTVT) has a profitability rating of 1 / 10.
Can you provide the financial health for VTVT stock?
The financial health rating of VTV THERAPEUTICS INC- CL A (VTVT) is 7 / 10.
Can you provide the expected EPS growth for VTVT stock?
The Earnings per Share (EPS) of VTV THERAPEUTICS INC- CL A (VTVT) is expected to grow by 0.14% in the next year.